In this guide
PT-141, also known as bremelanotide, is a melanocortin-receptor agonist. It's structurally derived from Melanotan II, but where that compound is a broad melanocortin activator, PT-141 is the more focused metabolite — and the receptor it focuses on is what makes it a distinct subject of research.
How the melanocortin mechanism works
The melanocortin system is a family of receptors (MC1R through MC5R) that govern everything from skin pigmentation to appetite to sexual function, depending on which receptor is engaged and where. PT-141 acts primarily at the MC4 receptor (MC4R), which is concentrated in the central nervous system. That receptor selectivity is the whole story of the compound.
Why "central" is the key word
Most compounds studied for arousal-related outcomes work at the periphery — on blood vessels and local tissue. PT-141 is different: it acts centrally, in the brain, on melanocortin pathways rather than on the vasculature. That distinct mechanism is why it's a separate line of research entirely, and why a pharmaceutical version of bremelanotide went through its own clinical development program.1 The compound sold here is supplied for laboratory research into that melanocortin pathway.
PT-141 vs Melanotan II
The two are related but not interchangeable. Melanotan II is a broad melanocortin agonist that strongly activates MC1R — the pigmentation receptor responsible for its association with tanning research — in addition to MC4R. PT-141 is the trimmed-down metabolite: it drops much of the MC1R pigmentation activity and concentrates on the MC4R central pathway. In short, Melanotan II is the broad tool and PT-141 is the focused one, which is why researchers pick between them based on which receptor they're actually studying.
Researching the melanocortin pathway? PT-141 is third-party tested and supplied for laboratory research, with a published COA where available.
View PT-141Frequently asked questions
What is PT-141? A melanocortin-receptor agonist (bremelanotide) that acts primarily at the central MC4 receptor.
How does it differ from Melanotan II? Melanotan II broadly activates melanocortin receptors including MC1R (pigmentation); PT-141 is the more MC4R-focused metabolite that acts centrally.
What does "acts centrally" mean? It works on receptors in the brain/central nervous system rather than on peripheral blood vessels — a different mechanism from vasodilator-type compounds.
Is PT-141 approved for human use? A pharmaceutical version has been developed for a specific medical indication, but the compound sold here is supplied strictly for in-vitro research and laboratory use only and is not intended for human consumption.
Research references
- Molinoff PB, Shadiack AM, Earle D, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96–102. PubMed ↗
For in-vitro research and laboratory use only. Not for human consumption. References are provided for scientific context and do not constitute a product claim.